Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.51 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.49 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.49 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.49 |
| ▸ | VNN1 | O95497 | 7/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8506547 | 0.98 | TAS1R3 (0.50) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL3976727 | 0.88 | TAS1R3 (0.53) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL7948494 | 0.85 | P4HB (0.40) | TAS1R3TAS1R1TAS1R2HDAC8HDAC1 | |
| Hydrochloric Acid SCHEMBL8506843 | 0.84 | MAPT (0.51) | HDAC8HDAC1HDAC6PLAUCYP1A2 | |
| SCHEMBL7083111 | 0.81 | TAS1R3 (0.51) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL25216423 | 0.81 | TAS1R3 (0.56) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL13407792 | 0.81 | TAS1R3 (0.59) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| Hydrochloric Acid SCHEMBL8503974 | 0.79 | S1PR1 (0.42) | TAS1R3TAS1R1TAS1R2HDAC8HDAC1 | |
| SCHEMBL4875325 | 0.79 | PRSS1 (0.42) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 | |
| SCHEMBL30641942 | 0.79 | VNN1 (0.54) | TAS1R3TAS1R1TAS1R2KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0612723-B1 | Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them | HOECHST AG (DE) | 1997-08-27 | — | — | EP | claimed |
| EP-0921117-B2 | Acylguanidines | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | HOECHST AKTIENGESELLSCHAFT | 2004-03-04 | — | — | US | disclosed |
| EP-0921117-B1 | Acylguanidines | AVENTIS PHARMA GMBH (DE) | 2003-12-10 | — | — | EP | disclosed |
| US-6632840-B1 | Inhibiting the Na+/H+ exchanger, treating at least one of arrhythmias and shock | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | disclosed |
| US-6617344-B2 | Suitable as antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment, and also for the treatment of angina pectoris. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-09 | — | — | US | disclosed |
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-07-24 | — | — | US | disclosed |
| CN-1373757-A | Heterocyclically substd, benzoylguanidine, method for production thereof, use thereof as medicament or means of diagnosis and medicaments contg. same | AVENTIS PHARMA GMBH (DE) | 2002-10-09 | — | — | CN | disclosed |
| US-6436999-B1 | REACTING GUANIDINE AND CARBOCYCLIC ACIDS, TO FORM COMPOUNDS LIKE BIS(3-METHYLSULFONYL-4-I-PROPYLBENZOYL)GUANIDINE, USED FOR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS AND AS PRODRUGS FOR SODIUM CHANNEL MODULATORS TO CONTROL BLOOD PRESSURE | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | disclosed |
| EP-1226124-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINE, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS A MEDICAMENT OR MEANS OF DIAGNOSIS AND A MEDICAMENT CONTAINING THE SAME | Aventis Pharma Deutschland GmbH (DE) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001030761-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINE, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS A MEDICAMENT OR MEANS OF DIAGNOSIS AND A MEDICAMENT CONTAINING THE SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-03 | — | — | WO | disclosed |
| EP-0640587-B1 | Diacyl substituted guanidins, process for their preparation, their use as medicament or diagnostic reagent and medicament containing them | HOECHST AG (DE) | 1999-12-29 | — | — | EP | disclosed |
| EP-0921117-A2 | Acylguanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-06-09 | — | — | EP | disclosed |
| US-5866610-A | Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical as inhibitors of the cellular NA+/H+ exchange or as a diagnostic, and pharmaceutical containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-02-02 | — | — | US | disclosed |
| US-5665739-A | CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-09 | — | — | US | disclosed |
| EP-0612723-B1 | Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them | HOECHST AG (DE) | 1997-08-27 | — | — | EP | disclosed |
| EP-0602523-B1 | Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them | HOECHST AG (DE) | 1996-12-11 | — | — | EP | disclosed |
| EP-0640587-A1 | Diacyl substituted guanidins, process for their preparation, their use as medicament or diagnostic reagent and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-01 | — | — | EP | disclosed |
| EP-0612723-A1 | Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-08-31 | — | — | EP | disclosed |
| EP-0602523-A1 | Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | TNNI3, HBG1, TNNT2 | TAS1R3 4127/4885TAS1R1 3012/4885TAS1R2 4057/4885 |
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | ADRA1B, ADRA1A, HYOU1 | TAS1R3 3957/4885TAS1R1 2840/4885TAS1R2 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.